Literature DB >> 23716560

Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasms.

Cristina Pérez1, Marien Pascual, José Ignacio Martín-Subero, Beatriz Bellosillo, Victor Segura, Eric Delabesse, Sara Álvarez, María José Larrayoz, José Rifón, Juan Cruz Cigudosa, Carles Besses, María José Calasanz, Nicholas C P Cross, Felipe Prósper, Xabier Agirre.   

Abstract

Most DNA methylation studies in classic Philadelphia-negative myeloproliferative neoplasms have been performed on a gene-by-gene basis. Therefore, a more comprehensive methylation profiling is needed to study the implications of this epigenetic marker in myeloproliferative neoplasms. Here, we have analyzed 71 chronic (24 polycythemia vera, 23 essential thrombocythemia and 24 primary myelofibrosis) and 13 transformed myeloproliferative neoplasms using genome-wide DNA methylation arrays. The three types of chronic Philadelphia-negative myeloproliferative neoplasms showed a similar aberrant DNA methylation pattern when compared to control samples. Differentially methylated regions were enriched in a gene network centered on the NF-κB pathway, indicating that they may be involved in the pathogenesis of these diseases. In the case of transformed myeloproliferative neoplasms, we detected an increased number of differentially methylated regions with respect to chronic myeloproliferative neoplasms. Interestingly, these genes were enriched in a list of differentially methylated regions in primary acute myeloid leukemia and in a gene network centered around the IFN pathway. Our results suggest that alterations in the DNA methylation landscape play an important role in the pathogenesis and leukemic transformation of myeloproliferative neoplasms. The therapeutic modulation of epigenetically-deregulated pathways may allow us to design targeted therapies for these patients.

Entities:  

Mesh:

Year:  2013        PMID: 23716560      PMCID: PMC3762098          DOI: 10.3324/haematol.2013.084160

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  49 in total

1.  Deletions of the transcription factor Ikaros in myeloproliferative neoplasms.

Authors:  R Jäger; H Gisslinger; F Passamonti; E Rumi; T Berg; B Gisslinger; D Pietra; A Harutyunyan; T Klampfl; D Olcaydu; M Cazzola; R Kralovics
Journal:  Leukemia       Date:  2010-05-27       Impact factor: 11.528

2.  Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?

Authors:  Hans Carl Hasselbalch
Journal:  Blood       Date:  2012-02-07       Impact factor: 22.113

3.  Epigenetic analysis of childhood acute lymphoblastic leukemia.

Authors:  Thomas L Dunwell; Luke B Hesson; Tatiana Pavlova; Veronika Zabarovska; Vladimir Kashuba; Daniel Catchpoole; Raffaella Chiaramonte; Anna T Brini; Mike Griffiths; Eamonn R Maher; Eugene Zabarovsky; Farida Latif
Journal:  Epigenetics       Date:  2009-04-12       Impact factor: 4.528

4.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

5.  Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms.

Authors:  Stephen T Oh; Erin F Simonds; Carol Jones; Matthew B Hale; Yury Goltsev; Kenneth D Gibbs; Jason D Merker; James L Zehnder; Garry P Nolan; Jason Gotlib
Journal:  Blood       Date:  2010-04-19       Impact factor: 22.113

Review 6.  The renaissance of interferon therapy for the treatment of myeloid malignancies.

Authors:  Jean-Jacques Kiladjian; Ruben A Mesa; Ronald Hoffman
Journal:  Blood       Date:  2011-03-09       Impact factor: 22.113

Review 7.  Antiviral actions of interferons.

Authors:  C E Samuel
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

8.  Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms.

Authors:  Nils H Thoennissen; Utz O Krug; Dhong Hyun Tony Lee; Norihiko Kawamata; Gabriela B Iwanski; Terra Lasho; Tamara Weiss; Daniel Nowak; Maya Koren-Michowitz; Motohiro Kato; Masashi Sanada; Lee-Yung Shih; Arnon Nagler; Sophie D Raynaud; Carsten Müller-Tidow; Ruben Mesa; Torsten Haferlach; D Gary Gilliland; Ayalew Tefferi; Seishi Ogawa; H Phillip Koeffler
Journal:  Blood       Date:  2010-01-12       Impact factor: 22.113

9.  Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia.

Authors:  Xabier Agirre; Amaia Vilas-Zornoza; Antonio Jiménez-Velasco; José Ignacio Martin-Subero; Lucia Cordeu; Leire Gárate; Edurne San José-Eneriz; Gloria Abizanda; Paula Rodríguez-Otero; Puri Fortes; José Rifón; Eva Bandrés; María José Calasanz; Vanesa Martín; Anabel Heiniger; Antonio Torres; Reiner Siebert; José Román-Gomez; Felipe Prósper
Journal:  Cancer Res       Date:  2009-05-12       Impact factor: 12.701

Review 10.  DNA methylation profiling in the clinic: applications and challenges.

Authors:  Holger Heyn; Manel Esteller
Journal:  Nat Rev Genet       Date:  2012-09-04       Impact factor: 53.242

View more
  26 in total

Review 1.  Novel and combination therapies for polycythemia vera and essential thrombocythemia: the dawn of a new era.

Authors:  Jan Philipp Bewersdorf; Amer M Zeidan
Journal:  Expert Rev Hematol       Date:  2020-11-01       Impact factor: 2.929

Review 2.  Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?

Authors:  R Tamari; T I Mughal; D Rondelli; R Hasserjian; V Gupta; O Odenike; V Fauble; G Finazzi; F Pane; J Mascarenhas; J Prchal; S Giralt; R Hoffman
Journal:  Bone Marrow Transplant       Date:  2015-02-09       Impact factor: 5.483

Review 3.  New Concepts of Treatment for Patients with Myelofibrosis.

Authors:  Prithviraj Bose; Mansour Alfayez; Srdan Verstovsek
Journal:  Curr Treat Options Oncol       Date:  2019-01-24

Review 4.  Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms.

Authors:  Tariq I Mughal; Alessandro M Vannucchi; Simona Soverini; Alexandra Bazeos; Raoul Tibes; Giuseppe Saglio; Omar Abdel-Wahab; Animesh Pardanani; Rudiger Hehlmann; Tiziano Barbui; Richard Van Etten; Ayalew Tefferi; John M Goldman
Journal:  Haematologica       Date:  2014-05       Impact factor: 9.941

5.  Loss of the proteostasis factor AIRAPL causes myeloid transformation by deregulating IGF-1 signaling.

Authors:  Fernando G Osorio; Clara Soria-Valles; Olaya Santiago-Fernández; Teresa Bernal; María Mittelbrunn; Enrique Colado; Francisco Rodríguez; Elena Bonzon-Kulichenko; Jesús Vázquez; Montserrat Porta-de-la-Riva; Julián Cerón; Antonio Fueyo; Juan Li; Anthony R Green; José M P Freije; Carlos López-Otín
Journal:  Nat Med       Date:  2015-12-21       Impact factor: 53.440

6.  Patients with triple-negative, JAK2V617F- and CALR-mutated essential thrombocythemia share a unique gene expression signature.

Authors:  Samah Alimam; William Villiers; Richard Dillon; Michael Simpson; Manohursingh Runglall; Alexander Smith; Prodromos Chatzikyriakou; Paul Lavender; Anju Kanda; Ken Mills; Beatriz Bellosillo Paricio; James Kaufman-Cook; Sophie Ord; Shahram Kordasti; Deepti Radia; Claire Woodley; Yvonne Francis; Ghulam Mufti; Donal P McLornan; Claire N Harrison
Journal:  Blood Adv       Date:  2021-02-23

7.  Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms.

Authors:  Vibe Skov; Mads Thomassen; Lasse Kjær; Christina Ellervik; Morten Kranker Larsen; Trine Alma Knudsen; Torben A Kruse; Hans C Hasselbalch
Journal:  PLoS One       Date:  2022-06-30       Impact factor: 3.752

Review 8.  Molecular classification of myeloproliferative neoplasms-pros and cons.

Authors:  Moosa Qureshi; Claire Harrison
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

Review 9.  Epigenetic Dysregulation of Myeloproliferative Neoplasms.

Authors:  Andrew Dunbar; Young Park; Ross Levine
Journal:  Hematol Oncol Clin North Am       Date:  2021-02-05       Impact factor: 3.722

Review 10.  Molecular pathogenesis of the myeloproliferative neoplasms.

Authors:  Graeme Greenfield; Mary Frances McMullin; Ken Mills
Journal:  J Hematol Oncol       Date:  2021-06-30       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.